LXR agonist promotes the up-regulation of its transcription target ApoE, which binds to the LRP8 receptor on MDSCs, thus reducing the survival rate of MDSCs and increasing the CD8+ and CD4+ T cells activated by tumor invasion, reversing the tumor immune evasion, and promoting anti-tumor immunity [56]. Here, CD8A is linked to neoplasm.